The Plasma Fractionation Market is projected to grow at a CAGR of ~10%, till 2035, claims Roots Analysis

The growing prevalence of rare and chronic diseases and the burgeoning demand for plasma-derived therapies have necessitated the advancements in blood plasma fractionation technologies in order to ensure a sustainable supply

LONDON, Sept. 21, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Plasma Fractionation Market, 2023-2035" report to its list of offerings.

Given the growing burden of chronic diseases, and limited treatment options for rare disorders, there is a need for more safe and versatile therapeutic options and plasma derived therapies have emerged as the effective alternatives. Driven by the growing demand for blood plasma derived therapies and the ongoing advancements in fractionation technologies, the plasma fractionation market is expected to grow at a noteworthy pace in the foreseen future.

To order this ~190 page report, which features 105+ figures and 130+ tables, please visit 

https://www.rootsanalysis.com/reports/plasma-fractionation-market.html

Key Market Insights

Presently, more than 85 plasma fractionation facilities have been established by over 35 plasma fractionators

The plasma fractionation industry is dominated by the presence of large plasma fractionation companies (more than 500 employees) and mid-sized plasma fractionation companies (51-500 employees), which collectively represent over 90% of the total number of players in this domain. In addition, more than 50% of the plasma fractionators are based in Asia-Pacific.

Till 2023, more than 45 partnerships have been established in the plasma fractionation industry

Nearly 85% of partnerships were established within the last four years. Majority of the instances were mergers and acquisitions (46%). It is worth noting that more than 65% of the deals were inked for the purpose of increasing blood plasma collection capabilities for plasma fractionation.

Over 60 expansions were reported by various players in blood plasma industry, during 2018-2023

Of these, 85% expansions were focused on establishing new plasma fractionation facilities, followed by those carried out for the expansion / establishment of new plants (13%). Furthermore, nearly 60% of the instances involved expansion of plasma collection / donation facilities.

Currently, the global installed plasma fractionation capacity is estimated to be nearly 130 million liters

At present, the major proportion (close to 90%) of this capacity is installed at facilities of large plasma fractionators (more than 500 employees). Further, nearly 80% of the overall plasma fractionation capacity is installed at plasma fractionation facilities based in Europe and Asia-Pacific.

By 2035, the market for plasma fractionation is likely to grow at an annualized rate of ~10%

In terms of type of company, the current market is driven by in-house plasma manufacturers (over 95%); this trend is unlikely to change in the foreseen future as well. However, contract service providers are anticipated to grow at a relatively faster pace. Further, it is worth highlighting that the market in Asia-Pacific, with respect to demand and supply, is likely to grow at a relatively faster pace in the long term.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/plasma-fractionation-market/request-sample.html 

Key Questions Answered

• How big is the plasma market?
• What is the market value of plasma?
• What is the fractionation process of blood?
• What is blood fractionation used for?
• What is the most commonly used plasma fractionation derivative?
• Which diseases / disorders are being treated by plasma-derived products, and has the largest share in the global plasma fractionation market?
• Which are the biggest companies / organizations in the plasma fractionation market?
• What is the future of plasma fractionation?

The financial opportunity within the plasma fractionation market has been analyzed across the following segments:

Type of Company

• In-house Manufacturers
• Contract Service Providers

Scale of Operation

•  Preclinical
• Clinical
• Commercial

Type of Plasma-derived Therapeutic Products Manufactured

• Albumins
• Coagulation Factors
• Immunoglobulins
• Protease Inhibitors
• Other Plasma-derived Products

Therapeutic Area of Plasma-derived Products

• Hematological Disorders
• Hepatic Disorders
• Immunological Disorders
• Neurological Disorders
• Other Disorders

Demand across Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Supply across Key Geographical Regions

• North America
• Europe
•  Asia-Pacific
• Rest of the World

The report features inputs from eminent industry stakeholders, according to whom, a significant increase in the demand for plasma-derived therapies are driving the growth of the plasma fractionation market.

The research also includes detailed profiles of key plasma fractionators (listed below) engaged in plasma fractionation industry; each profile features a brief overview of the company, its financial information (if available), details on plasma fractionation portfolio, recent developments and an informed future outlook.

• Baxter
• Grifols
• Kedrion
• Octapharma
• CSL
• Takeda Pharmaceutical

For additional details, please visit https://www.rootsanalysis.com/reports/plasma-fractionation-market.html

You may also be interested in the following titles:

1.  Plasmid DNA Manufacturing Market: Industry Trends and Global Forecasts, 2023-2035

2.  Patient Engagement Solutions Market: Industry Trends and Global Forecasts, 2023-2035

3.  Nanoparticle Formulation Market: Industry Trends and Global Forecasts, 2023-2035

4.  Conjugation and Labeling Services Market: Industry Trends and Global Forecasts, 2023-2035

5.  Cannabis Testing Market: Industry Trends and Global Forecasts, 2023-2035

Contact:

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.chaudhary@rootsanalysis.com 

Logo: https://mma.prnewswire.com/media/742223/Roots_Analysis_Logo.jpg